Enanta Pharmaceuticals (ENTA) Stock: Buy, Sell, or Hold?
$11.12
-0.48 (-4.14%)
âŧ
5d:
+10.32%
30d:
-0.54%
90d:
-15.5%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 16, 2026
3d
Protect ENTA Gains
Updated Nov 12, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (82%)
Quality Score
44/100
Position
SLIGHTLY LOW
30-Day Fair Range
$10.83 â $12.10
Position: SLIGHTLY LOW
Forward P/E & Valuation
-4.9x
Next 12M consensus est.
Wall Street Target
$21.83
+88.2% upside
Options IV & Volume
22th pct IV
HIGH volume confirmation
Support / Resistance
$10.05 / $11.75
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: ENTA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
Get Alerted When ENTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: ENTA is currently trading at $11.12, which is considered slightly low relative to its 30-day fair value range of $10.83 to $12.10.
Technical Outlook: Technically, ENTA is in a strong downtrend. Immediate support is located at $10.05, while resistance sits at $11.75. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: The stock scores a mixed 46/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (22th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $21.83 (+88.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ENTA is in a strong downtrend. Immediate support is located at $10.05, while resistance sits at $11.75. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: The stock scores a mixed 46/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (22th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $21.83 (+88.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$10.83 -
$12.10
Company Quality Score
44/100
(HOLD)
Options IV Signal
22th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
82.1%
Trading Range & Key Levels
30-Day Trading Range
$10.83 -
$12.10
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
Âą$2.23
(20.1%)
Support Level
$10.05
Resistance Level
$11.75
Current Trend
Strong Downtrend
Technical data as of
Nov 11, 2026
Protect Your Profits
Holding ENTA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 22th percentile)
- NEUTRAL: Mixed technical signals (46/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.1%)
- BULLISH: Trading 88.2% below Wall St target ($21.83)
- WARNING: Composite score 44/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-4.89
Wall Street Target
$21.83
(+88.2%)
Revenue Growth (YoY)
-21.6%
Earnings Growth (YoY)
-66.2%
Profit Margin
-96.9%
Share ENTA Analysis
Share this live ENTA analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (ENTA)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Oct 26, 2026
Daily AI digest
AI Retail Discussion Summary:
Enanta Pharmaceuticals announced the first patient dosing in a Phase 1 study for its investigational RNAi therapeutic, RESOLVE, for the treatment of chronic hepatitis B.
Key Retail Themes:
Clinical trials
Hepatitis B treatment
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 1:51 PM ET
Data refreshes hourly during market hours. Next update: 2:51 PM
Data refreshes hourly during market hours. Next update: 2:51 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENTA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
25 analysts |
$261 | 38 SELL |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 41 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 42 HOLD |
|
SNDX
Syndax Pharmaceuticals IâĻ |
STRONG BUY
12 analysts |
$35 | 58 HOLD |
|
ACHV
Achieve Life Sciences Inc |
STRONG BUY
12 analysts |
$14 | 56 HOLD |
Advanced ENTA Option Strategies
Professional options setups generated by AI based on today's ENTA price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive ENTA Research Pages
